Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Development Award (Details Narrative)

v3.7.0.1

Development Award (Details Narrative)			1 Months Ended		3 Months Ended	12 Months Ended
Development Award (Details Narrative)	Aug. 31, 2016 USD ($)	Apr. 20, 2015 USD ($) Installments	Nov. 30, 2015 USD ($)	May 31, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2016 USD ($)
Development Award [Line Items]
Grants receivable						$ 1,000,000
Deferred revenue				$ 1,250,000		4,500,000
Cystic Fibrosis Foundation Therapeutics Inc [Member]
Development Award [Line Items]
Amount received upon execution of award agreement	$ 1,000,000		$ 1,250,000	$ 1,250,000	$ 1,250,000	500,000
Deferred revenue						$ 500,000
Oral Anti-inflammatory Drug [Member] \| Cystic Fibrosis Foundation Therapeutics Inc [Member]
Development Award [Line Items]
Amount received upon execution of award agreement		$ 4,500,000
Oral Anti-inflammatory Drug [Member] \| Maximum [Member]
Development Award [Line Items]
Development award received		$ 5,000,000
JBT-101 [Member]
Development Award [Line Items]
Percentage of royalty over receivables under agreement		5.00%
Number of installments \| Installments		3
Royalty payment, sales target		$ 500,000,000
Payment due period after the first commercial sale		90 days
JBT-101 [Member] \| Upon Transfer Sale Or Licensing [Member]
Development Award [Line Items]
Royalty payable		$ 15,000,000
JBT-101 [Member] \| Maximum [Member] \| Upon Commercialization Of The Product [Member]
Development Award [Line Items]
Royalty payable		25,000,000
JBT-101 [Member] \| Maximum [Member] \| Upon Reaching The Sales Target [Member]
Development Award [Line Items]
Royalty payable		$ 5,000,000

- Definition

Deferred Revenue Gross

+ References

No definition available.

+ Details

Name:	CRBP_DeferredRevenueGross
Namespace Prefix:	CRBP_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Development Award [Line Items]

+ References

No definition available.

+ Details

Name:	CRBP_DevelopmentAwardLineItems
Namespace Prefix:	CRBP_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of installments.

+ References

No definition available.

+ Details

Name:	CRBP_NumberOfInstallments
Namespace Prefix:	CRBP_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Payment due period after the first commercial sale.

+ References

No definition available.

+ Details

Name:	CRBP_PaymentDuePeriodAfterTheFirstCommercialSale
Namespace Prefix:	CRBP_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty over receivables under agreement.

+ References

No definition available.

+ Details

Name:	CRBP_PercentageOfRoyaltyOverReceivablesUnderAgreement
Namespace Prefix:	CRBP_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty payment sales target.

+ References

No definition available.

+ Details

Name:	CRBP_RoyaltyPaymentSalesTarget
Namespace Prefix:	CRBP_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355

+ Details

Name:	us-gaap_GainContingencyUnrecordedAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_GrantsReceivableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=CRBP_CysticFibrosisFoundationTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_OralAntiinflammatoryDrugMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_JBTOneZeroOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=CRBP_UponTransferSaleOrLicensingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=CRBP_UponCommercializationOfTheProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=CRBP_UponReachingTheSalesTargetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: